Recombinant Fusion Proteins
"Recombinant Fusion Proteins" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Recombinant proteins produced by the GENETIC TRANSLATION of fused genes formed by the combination of NUCLEIC ACID REGULATORY SEQUENCES of one or more genes with the protein coding sequences of one or more genes.
| Descriptor ID |
D011993
|
| MeSH Number(s) |
D12.776.828.300
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Recombinant Fusion Proteins".
Below are MeSH descriptors whose meaning is more specific than "Recombinant Fusion Proteins".
This graph shows the total number of publications written about "Recombinant Fusion Proteins" by people in this website by year, and whether "Recombinant Fusion Proteins" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 1 | 6 | 7 |
| 1995 | 2 | 6 | 8 |
| 1996 | 1 | 6 | 7 |
| 1997 | 0 | 7 | 7 |
| 1998 | 1 | 4 | 5 |
| 1999 | 0 | 9 | 9 |
| 2000 | 1 | 9 | 10 |
| 2001 | 2 | 5 | 7 |
| 2002 | 0 | 13 | 13 |
| 2003 | 0 | 19 | 19 |
| 2004 | 1 | 15 | 16 |
| 2005 | 0 | 12 | 12 |
| 2006 | 3 | 9 | 12 |
| 2007 | 1 | 13 | 14 |
| 2008 | 2 | 9 | 11 |
| 2009 | 2 | 7 | 9 |
| 2010 | 1 | 9 | 10 |
| 2011 | 1 | 9 | 10 |
| 2012 | 2 | 14 | 16 |
| 2013 | 2 | 5 | 7 |
| 2014 | 5 | 3 | 8 |
| 2015 | 2 | 10 | 12 |
| 2016 | 1 | 2 | 3 |
| 2017 | 0 | 4 | 4 |
| 2018 | 2 | 2 | 4 |
| 2019 | 2 | 2 | 4 |
| 2020 | 0 | 1 | 1 |
| 2021 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Recombinant Fusion Proteins" by people in Profiles.
-
Frias JP, Bonora E, Nev?rez Ruiz L, Hsia SH, Jung H, Raha S, Cox DA, Bethel MA, Konig M. Efficacy and safety of dulaglutide 3.0?and 4.5?mg in patients aged?younger than?65 and?65?years or older: Post hoc analysis of the AWARD-11 trial. Diabetes Obes Metab. 2021 10; 23(10):2279-2288.
-
Hew BE, Pangburn MK, Vogel CW, Fritzinger DC. Identification of intermolecular bonds between human factor B and Cobra Venom Factor important for C3 convertase stability. Toxicon. 2020 Sep; 184:68-77.
-
Zhang B, Han Z, Kumar S, Gupta M, Su WW. Intein-ubiquitin chimeric domain for coordinated protein coexpression. J Biotechnol. 2019 Oct 10; 304:38-43.
-
Dung TT, Lee UJ, Kim MH, Kim KE, Cho HM, Fermin CD, Kim DH, Kim M. PAS1-modified optical SIS sensor for highly sensitive and specific detection of toluene. Biosens Bioelectron. 2019 Sep 15; 141:111469.
-
Hew BE, Fritzinger DC, Pangburn MK, Vogel CW. Identification of functionally important amino acid sequences in cobra venom factor using human C3/Cobra venom factor hybrid proteins. Toxicon. 2019 Sep; 167:106-116.
-
Nguyen H, Ward WS, James NG. Spatial and temporal resolution of mORC4 fluorescent variants reveals structural requirements for achieving higher order self-association and pronuclei entry. Methods Appl Fluoresc. 2019 May 16; 7(3):035002.
-
Furuya H, Chan OTM, Pagano I, Zhu C, Kim N, Peres R, Hokutan K, Alter S, Rhode P, Rosser CJ. Effectiveness of two different dose administration regimens of an IL-15 superagonist complex (ALT-803) in an orthotopic bladder cancer mouse model. J Transl Med. 2019 01 17; 17(1):29.
-
Hung CY, Zhang H, Castro-Lopez N, Ostroff GR, Khoshlenar P, Abraham A, Cole GT, Negron A, Forsthuber T, Peng T, Galgiani JN, Ampel NM, Yu JJ. Glucan-Chitin Particles Enhance Th17 Response and Improve Protective Efficacy of a Multivalent Antigen (rCpa1) against Pulmonary Coccidioides posadasii Infection. Infect Immun. 2018 11; 86(11).
-
Burroughs AF, Eluhu S, Whalen D, Goodwin JS, Sakwe AM, Arinze IJ. PML-Nuclear Bodies Regulate the Stability of the Fusion Protein Dendra2-Nrf2 in the Nucleus. Cell Physiol Biochem. 2018; 47(2):800-816.
-
Sun W, Liu H, Kim Y, Karras N, Pawlowska A, Toomey D, Kyono W, Gaynon P, Rosenthal J, Stein A. First pediatric experience of SL-401, a CD123-targeted therapy, in patients with blastic plasmacytoid dendritic cell neoplasm: report of three cases. J Hematol Oncol. 2018 05 02; 11(1):61.